Peter Nash Selected Research

Rituximab (Mabthera)

1/2023	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
6/2017	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Nash Research Topics

Disease

66	Psoriatic Arthritis 03/2024 - 06/2004
46	Rheumatoid Arthritis 03/2024 - 06/2004
26	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2024 - 06/2004
14	Infections 04/2022 - 08/2014
11	Ankylosing Spondylitis 11/2023 - 07/2006
10	Necrosis 11/2023 - 11/2013
7	Pain (Aches) 03/2024 - 12/2016
7	Neoplasms (Cancer) 01/2023 - 08/2014
6	Arthritis (Polyarthritis) 03/2024 - 05/2007
6	Herpes Zoster 01/2023 - 01/2016
6	Systemic Scleroderma (Systemic Sclerosis) 09/2016 - 09/2009
5	Fatigue 01/2022 - 05/2007
4	Ulcerative Colitis 01/2021 - 01/2019
4	Pulmonary Arterial Hypertension 09/2016 - 11/2011
3	Axial Spondyloarthritis 01/2023 - 10/2021
3	Chronic Disease (Chronic Diseases) 01/2022 - 01/2019
2	COVID-19 11/2023 - 01/2023
2	Non-Radiographic Axial Spondyloarthritis 01/2023 - 10/2021
2	Sacroiliitis 01/2023 - 01/2023
2	Atopic Dermatitis (Atopic Eczema) 01/2023 - 11/2020
2	Rheumatic Diseases (Rheumatism) 10/2022 - 06/2018
2	Nail Diseases (Nail Disease) 05/2022 - 05/2007
2	Diarrhea 04/2022 - 06/2004
2	Headache (Headaches) 04/2022 - 02/2022
2	Crohn Disease (Crohn's Disease) 11/2020 - 01/2019
2	Injection Site Reaction 01/2019 - 08/2014
2	Dyspnea (Shortness of Breath) 10/2009 - 06/2008
1	Uveitis 03/2024
1	Venous Thromboembolism 11/2023
1	Adult-Onset Still's Disease 01/2023
1	Cytokine Release Syndrome 01/2023
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023
1	Castleman Disease (Castleman's Disease) 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Neuromyelitis Optica (Devic's Disease) 01/2023
1	Skin Neoplasms (Skin Cancer) 01/2023
1	Takayasu Arteritis (Arteritis, Takayasu's) 01/2023
1	Giant Cell Arteritis (Horton Disease) 01/2023
1	Low Back Pain (Lumbago) 01/2023
1	Dyspepsia (Indigestion) 04/2022
1	Tuberculosis (Tuberculoses) 04/2022
1	Nasopharyngitis 04/2022
1	Nausea 04/2022
1	Oral Candidiasis (Thrush) 04/2022
1	Opportunistic Infections (Opportunistic Infection) 04/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 04/2022
1	Anemia 04/2022

Drug/Important Bio-Agent (IBA)

32	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 09/2006
21	Antirheumatic Agents (DMARD)IBA 03/2024 - 09/2006
19	tofacitinibIBA 01/2023 - 03/2013
19	Janus Kinase InhibitorsIBA 01/2023 - 06/2017
18	Adalimumab (Humira)FDA Link 03/2024 - 12/2016
17	secukinumabIBA 03/2024 - 10/2015
14	ixekizumabIBA 10/2023 - 10/2017
11	ametantrone (HAQ)IBA 11/2023 - 11/2011
9	upadacitinibIBA 11/2023 - 01/2021
8	Etanercept (Enbrel)FDA Link 01/2023 - 03/2013
7	Tumor Necrosis Factor InhibitorsIBA 03/2024 - 06/2017
7	golimumab FDA Link 01/2023 - 04/2008
6	Interleukin-17 (Interleukin 17)IBA 03/2024 - 10/2015
6	GLPG0634IBA 03/2024 - 01/2021
6	Abatacept (Orencia)FDA Link 01/2023 - 05/2013
4	Monoclonal AntibodiesIBA 11/2023 - 08/2009
4	Infliximab (Remicade)FDA Link 01/2023 - 06/2017
4	Leflunomide (Arava)FDA LinkGeneric 01/2023 - 06/2004
4	GlucocorticoidsIBA 01/2018 - 05/2003
3	guselkumabIBA 03/2024 - 01/2020
3	bimekizumabIBA 03/2024 - 01/2024
3	C-Reactive ProteinIBA 03/2024 - 10/2021
3	Certolizumab Pegol FDA Link 06/2023 - 06/2017
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2023 - 01/2021
3	Janus KinasesIBA 01/2022 - 06/2017
3	apremilastIBA 12/2021 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 09/2016 - 10/2009
3	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2016 - 06/2012
2	InterleukinsIBA 03/2024 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2023 - 08/2009
2	tocilizumab (atlizumab)FDA Link 01/2023 - 06/2017
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2023 - 06/2017
2	Biosimilar PharmaceuticalsIBA 01/2023 - 06/2017
2	baricitinibIBA 01/2023 - 06/2017
2	Rituximab (Mabthera)FDA Link 01/2023 - 06/2017
2	sarilumabIBA 01/2023 - 06/2017
2	pro-brain natriuretic peptide (1-76)IBA 01/2013 - 06/2012
1	Interleukin-23 Subunit p19IBA 03/2024
1	omega-Chloroacetophenone (Mace)IBA 11/2023
1	Antiviral Agents (Antivirals)IBA 11/2023
1	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	AutoantibodiesIBA 01/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	CytokinesIBA 10/2022
1	vinyltriethoxysilane (VTES)IBA 04/2022
1	Hemoglobins (Hemoglobin)IBA 02/2022
1	Prostaglandins AIBA 02/2022
1	N-phthaloylglutamic acidIBA 12/2021

Therapy/Procedure

20	Therapeutics 03/2024 - 07/2006
3	Biological Therapy 10/2022 - 11/2005
2	Activities of Daily Living (ADL) 10/2009 - 06/2008
1	Retreatment 01/2023